What is PSNL's market cap?

$1.69B, based on the Nov 4 close of $15.79.

Does Personalis pay a dividend?

No regular cash dividend has been paid in the last year.

How much of PSNL is sold short?

6.8M shares, 10.1% of float, as of Oct 15, 2026.

What sector is PSNL in?

Healthcare, in the Medical Labs industry.

NASDAQ · PSNLHealthcareMedical Labs

Personalis, Inc. Common Stock (PSNL)

$15.79+0.25%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$15.76▲ 75.11% in range

Nov 3, 2025Low $5.04 · High $18.38Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

Personalis closed at $15.79 on Nov 4, up 0.25%, 14.1% below its 52-week closing high. Volume of 2.2M shares was 0.95× its 20-day average (close to normal).

Split-adjusted performance: -1.5% over one month, +160.1% over six months, +75.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $22.36M, up 30.0% from a year earlier, with a net margin of -141.7%.

Short interest was 6.8M shares at the Oct 15 settlement, down 19.4% from the prior report (10.1% of float, 2.6 days to cover).

Market cap$1.69B106.8M shares

Revenue · quarter$22.4M+30.0% YoY

Diluted EPS$-0.30—

P/E · TTM—P/S 24.2×

Net margin-141.7%Gross 21.2%

Dividend yieldNone

52-week range5.04 – 18.38−14.1% from high

Volume2.2M0.95× 20-day avg

Volatility · 60d41.3%Annualised

Short % of float10.1%2.6 days to cover

Net cash$212.7MCash $212.7M

Next earnings—Not scheduled

Split-adjusted performance

1W −1.3%1M −1.5%3M +21.2%6M +160.1%YTD +98.4%1Y +75.4%3Y +1562.5%5Y −14.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum91

Revenue growth61

Net margin19

Value (low P/E)—

Size48

Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.

Short interest

Details →

Shares short6.8M−19.4% vs prior

Days to cover2.6Settled Oct 15

% of float10.1%

Short vol. 10d53.6%of daily volume

Closest peers by size in Medical Labs

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
PSNLPersonalis	$15.79	+0.25%	+160.1%	+30.0%	−141.7%	—	$1.69B
FTREFortrea Holdings	$20.83	−0.57%	+33.2%	−1.4%	0.1%	—	$2.01B	Compare
LMRILumexa Imaging Holdings	$13.10	+16.76%	+27.4%	—	1.0%	—	$1.26B	Compare
FRNMFreenome	$11.30	−1.48%	—	—	—	—	$1.21B	Compare
CSTLCastle Biosciences	$35.75	+1.74%	+44.4%	+20.1%	−2.0%	—	$1.09B	Compare
CELCCelcuity	$69.24	−0.69%	−50.3%	—	—	—	$3.39B	Compare
VCYTVeracyte	$52.52	+4.43%	+27.5%	+15.5%	17.0%	36.9	$4.22B	Compare
CDNACareDx	$85.86	−2.95%	+309.8%	+39.3%	13.8%	35.1	$4.51B	Compare
FLGTFulgent Genetics	$19.68	+1.60%	+31.9%	+4.4%	−34.6%	—	$541.5M	Compare

News about Personalis

All news →

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)GlobeNewswire Inc. · Sep 23, 2026▼ Negative PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AIGlobeNewswire Inc. · Aug 4, 2026▼ Negative PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to TempusGlobeNewswire Inc. · Aug 3, 2026▼ Negative Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc. · Jul 30, 2026▼ Negative

Quick answers

What does Personalis do?: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services.
What is PSNL's market cap?: $1.69B, based on the Nov 4 close of $15.79.
Does Personalis pay a dividend?: No regular cash dividend has been paid in the last year.
How much of PSNL is sold short?: 6.8M shares, 10.1% of float, as of Oct 15, 2026.
What sector is PSNL in?: Healthcare, in the Medical Labs industry.

About Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

HQ: Fremont, CA260 employeesListed Jun 20, 2019personalis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology